Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Delay Means New EU Clinical Trial Rules May Not Be Transferred To UK

Executive Summary

With the implementation of the EU Clinical Trials Regulation now postponed to the second half of 2019, it is unlikely that its provisions will be taken over into UK legislation as part of the Brexit “Repeal Bill” that will convert all EU laws and regulations into domestic UK law.

You may also be interested in...

EU Issues GMP Guide For Investigational Drugs Under Clinical Trials Regulation

A new EU guideline explains how manufacturers and importers of investigational medicinal products can comply with the provisions of a 2017 delegated regulation specifying good manufacturing practice requirements and inspection procedures for such products.

US Pharma Firms Warn ‘Hard’ Brexit Will Impact UK Investments; Clinical Trials A Casualty Of Uncertainty

A group of US pharmaceutical majors have said that their investments in the UK could be at risk if the UK leaves the EU without a Brexit deal, and that the UK could become a “secondary market” in terms of new drug launches. Meanwhile a major UK research institute says that the uncertainty is already causing drug sponsors to think twice about running clinical trials in the UK. A slowdown in pharma market growth is also foreseen.

Brexit Hits Life Science Investment Decisions As UK Risks Exclusion From Key EU Projects

The chief executives of the APBI and the BIA have told the House of Lords’ Science and Technology Committee that Brexit uncertainty is having an impact on life science investment decisions and that the UK may not be able to benefit from key EU legislative initiatives that it helped to create.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts